1. Home
  2. CII vs TRAX Comparison

CII vs TRAX Comparison

Compare CII & TRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock Capital and Income Fund Inc.

CII

Blackrock Capital and Income Fund Inc.

SELL

Current Price

$23.32

Market Cap

1.1B

Sector

Finance

ML Signal

SELL

TRAX

First Tracks Biotherapeutics Inc. Ordinary Shares

SELL

Current Price

$34.18

Market Cap

1.2B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CII
TRAX
Founded
2004
2025
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
2004
2026

Fundamental Metrics

Financial Performance
Metric
CII
TRAX
Price
$23.32
$34.18
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
★ $72.50
AVG Volume (30 Days)
62.5K
★ 1.0M
Earning Date
01-01-0001
11-12-2026
Dividend Yield
★ 6.17%
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.43
$15.69
52 Week High
$26.17
$49.91

Technical Indicators

Market Signals
Indicator
CII
TRAX
Relative Strength Index (RSI) 33.30 47.58
Support Level $22.26 $30.11
Resistance Level $23.61 $48.94
Average True Range (ATR) 0.34 2.85
MACD -0.06 0.40
Stochastic Oscillator 2.91 42.59

Price Performance

Historical Comparison
CII
TRAX

About CII Blackrock Capital and Income Fund Inc.

Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its investment objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing in a portfolio of equity securities of U.S. and foreign issuers. It may invest directly in such securities or synthetically through the use of derivatives. It also seeks to achieve its investment objective by employing a writing (selling) call and put options.

About TRAX First Tracks Biotherapeutics Inc. Ordinary Shares

First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.

Share on Social Networks: